We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01707758
Recruitment Status : Withdrawn (Trial terminated - Nanoscale Company out of business)
First Posted : October 16, 2012
Last Update Posted : May 16, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

Condition or disease
Pancreatic Cancer

Detailed Description:
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion

Study Design

Study Type : Observational
Actual Enrollment : 0 participants
Time Perspective: Prospective
Official Title: Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Study Start Date : October 2012
Primary Completion Date : February 2013
Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

pancreatic cancer
This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.

Outcome Measures

Biospecimen Retention:   Samples Without DNA
Approximately 1 tablespoon of blood will be collected from each subject.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients will be recruited from the University of Kansas Cancer Center prior to any treatment for their pancreatic cancer. Final histology and staging will be recorded and correlated with protease concnentration. Healthy subjects will be recruited from the University of Kansas and Kansas State community.

Inclusion Criteria:

Inclusion Criteria for Pancreatic Cancer Patients:

  • Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis.
  • Patients will have had no prior treatment or surgery

Inclusion Criteria for Healthy Subjects:

  • Subjects will have no prior history of any cancer

Exclusion Criteria:

Exclusion Criteria for Pancreatic Cancer Patients

  • Any prior treatment for pancreatic cancer
  • Poorly controlled diabetes

Exclusion Criteria for Healthy Subjects

  • Poorly controlled diabetes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01707758

Sponsors and Collaborators
University of Kansas
Principal Investigator: Stephen Williamson, MD University of Kansas Medical Center Cancer Center
More Information

Responsible Party: University of Kansas
ClinicalTrials.gov Identifier: NCT01707758     History of Changes
Other Study ID Numbers: 13421
First Posted: October 16, 2012    Key Record Dates
Last Update Posted: May 16, 2013
Last Verified: May 2013

Keywords provided by University of Kansas Medical Center ( University of Kansas ):
pancreatic cancer
cell survival
tumor progression
tissue remodeling/invasion

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases